Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 11/20 | 0.55 |
| ▸ | NPC1 | O15118 | 10/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL710217 | 1.00 | PAX8 (0.56) | PAX8RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL12923109 | 0.91 | PAX8 (0.63) | PAX8RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL711460 | 0.86 | KDM4E (0.59) | PAX8RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL711461 | 0.86 | KDM4E (0.59) | PAX8RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL708372 | 0.83 | PAX8 (0.56) | PAX8RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL708682 | 0.83 | PAX8 (0.56) | PAX8RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL708683 | 0.83 | PAX8 (0.56) | PAX8RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL712709 | 0.83 | RAB9A (0.64) | PAX8RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL714075 | 0.83 | PAX8 (0.56) | PAX8RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL714074 | 0.83 | PAX8 (0.56) | PAX8RAB9ANPC1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112300085-A | Alkenyl method of methyl heterocyclic compound | 温州大学 | 2021-02-02 | — | — | CN | disclosed |
| US-8124625-B2 | enhancing the expression of apoAI; prevention or therapy of dislipidemia | SHIONOGI & CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8124625-B2 | enhancing the expression of apoAI; prevention or therapy of dislipidemia | SHIONOGI & CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8124625-B2 | enhancing the expression of apoAI; prevention or therapy of dislipidemia | SHIONOGI & CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8053445-B2 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-8053445-B2 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-8053445-B2 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20090036457-A1 | Utilities of olefin derivatives | YAMAMORI TERUO | 2009-02-05 | — | — | US | disclosed |
| US-20090036457-A1 | Utilities of olefin derivatives | YAMAMORI TERUO | 2009-02-05 | — | — | US | disclosed |
| US-20090036457-A1 | Utilities of olefin derivatives | YAMAMORI TERUO | 2009-02-05 | — | — | US | disclosed |
| US-20040242615-A1 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242615-A1 | Utilities of olefin derivatives | APOL1, NR1H2, APOB | PAX8 4417/4885RAB9A 4723/4885NPC1 19/4885 |
| US-20090036457-A1 | Utilities of olefin derivatives | APOL1, APOB, NR1H2 | PAX8 4618/4885RAB9A 4606/4885NPC1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.